AndroGel 1% testosterone gel is for the treatment of men with low or no testosterone.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) has obtained US Food and Drug Administration (FDA) approval for its AndroGel 1% testosterone gel for the treatment of men with low or no testosterone.
AndroGel is a bioequivalent of the AbbVie Inc. (Nasdaq: ABBV) testosterone gel. According to Symphony Health, the gel has $705 million in annual sales.
Published by Globes [online], Israel business news - www.globes-online.com - on February 6, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013